

# Hansa Medical

## Increase of Number of Shares and Votes in Hansa Medical AB (publ)

Lund, Sweden, October 31, 2018 - Hansa Medical AB (NASDAQ Stockholm:HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company's registered share capital and number of outstanding shares and votes have increased during the month of October 2018.

As previously announced on September 6, 2018. Hansa's board of directors resolved to issue 391,503 class C shares, by virtue of authorization by the general meeting held on May 29, 2018. Furthermore, the Hansa general meeting resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 50,000 ordinary shares have been issued.

All class C shares are owned by the Company. The share issue forms part of the Company's long-term incentive program, and the purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018.

As of today, the total number of registered and outstanding shares of Hansa amounts to 38,904,889, whereof 38,183,125 are ordinary shares and 721,764 are class C shares. As of today, the number of votes in Hansa amounts to 38,255,301.4, and the registered share capital amounts to SEK 38,904,889.

*This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00am CET on October 31, 2018.*

### About Hansa Medical

Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company's lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.

**For further information, please contact:**

#### Company:

Emanuel Björne, Vice President Business Development and Investor Relations  
Hansa Medical AB (Publ)  
Mobile: +46707175477  
E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

#### Swedish Investor and Media Relations:

Cord Communications  
Mikael Widell  
+46 70-311 99 60

#### U.K. Investor and Media Relations

FTI Consulting  
Simon Conway/ Stephanie Cuthbert  
+44 (0)20 3727 1000

# Hansa Medical

**U.S. Investor and Media Relations:**

Argot Partners

Stephanie Marks / David Rosen (media)

+1 212 600 1902